HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

AIDS

Volumn 15, Issue 9, 2001, Pages

  Ruiz, Lidia ^a   Carcelain, Guislaine ^b   Martínez Picado, Javier ^a   Frost, Simon ^c   Marfil, Silvia ^a   Paredes, Roger ^a   Romeu, Joan ^a   Ferrer, Esther ^a   Morales Lopetegi, Kristina ^a   Autran, Brigitte ^c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Centre for HIV Research   (United Kingdom)

Author keywords

Chronic HIV infection; HAART; HIV dynamics; HIV specific T cell response; Structured treatment interruption

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; RECOMBINANT INTERLEUKIN 2; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 0035875860     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00001     Document Type: Article

References (35)

1. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
2. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
3. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
4. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease
5. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
6. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
7. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
8. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
9. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
10. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
11. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
12. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
13. Antiretroviral resistance during successful therapy of HIV type 1 infection
14. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
15. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
16. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
17. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
18. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
19. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
20. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
21. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load
22. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
23. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
24. Immune control of HIV-1 after early treatment of acute infection
25. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years
26. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
27. Viral dynamics in human immunodeficiency virus type 1 infection
28. Control of HIV despite the discontinuation of antiretroviral therapy
29. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
30. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
31. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
32. Molecular determinants of macrophage tropism and viral persistence: Importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus
33. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy